- Liz Highleyman | 29 November 2013
A dual regimen of entecavir (Baraclude) plus tenofovir
(Viread) for 48 weeks led to virological response and was generally
well-tolerated among people with chronic hepatitis B who had experienced treatment failure with ...
- Michael Carter | 27 November 2013
The experimental
hepatitis C virus (HCV) protease inhibitor is efficacious across a range of
subgroups, according to research presented to the recent Liver Meeting 2013,
the 64th annual meeting of the American Association ...
- Michael Carter | 22 November 2013
The
investigational hepatitis C virus (HCV) protease inhibitor faldaprevir is a
safe and effective treatment for people who did not respond to a previous
course of HCV treatment, results of a study presented ...
- Liz Highleyman | 15 November 2013
Hepatitis C treatment that leads to viral suppression
significantly reduces the likelihood of liver disease progression and
liver-related mortality, but most people with hepatitis C remain untreated, according to a
presentation at The
Liver ...
- Liz Highleyman | 14 November 2013
A dual oral regimen of sofosbuvir
plus ribavirin led to sustained response for 93% of people with genotype 2 hepatitis C
treated for 12 weeks and 85% of people with genotype 3 ...
- Liz Highleyman | 13 November 2013
The hepatitis C protease inhibitor faldaprevir plus pegylated interferon
and ribavirin improved 4-week sustained response rates for HIV-positive people with genotype 1 hepatitis C co-infection in the STARTVerso4 trial, according to
a ...
- Liz Highleyman | 12 November 2013
An
interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir
taken for 24 weeks led to sustained virological response (SVR12) in 85% of Japanese
patients with hepatitis C virus subtype 1b, according to ...
- Liz Highleyman | 11 November 2013
At least 95% of newly treated people with genotype 1
hepatitis C and prior non-responders achieved sustained virological
response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or
without ribavirin, according to ...
- Liz Highleyman | 08 November 2013
An interferon-free combination of sofosbuvir plus
ribavirin administered before liver transplantation prevented hepatitis C
recurrence in nearly two-thirds of patients, while the same regimen led to
early viral clearance in three-quarters of those ...
- Liz Highleyman | 06 November 2013
Long-term treatment with entecavir can
reduce the likelihood that people with chronic hepatitis B will develop
hepatocellular carcinoma, according to findings presented this week at The
Liver Meeting 2013, the 64th annual meeting ...
- Liz Highleyman | 06 November 2013
An interferon-free regimen of sofosbuvir plus
ribavirin taken for 24 weeks cured hepatitis C infection in three quarters of previously untreated HIV-positive
people co-infected with hepatitis C virus (HCV) genotype 1, while ...
- Liz Highleyman | 05 November 2013
A
12-week all-oral combination of simeprevir plus sofosbuvir led to sustained
virological response in 93% of genotype 1 prior null responders with
mild-to-moderate liver fibrosis, working as well as a longer course of
treatment ...
- Keith Alcorn | 05 November 2013
A combination of three direct-acting antivirals developed by
Bristol-Myers Squibb cured chronic hepatitis C infection in over 90% of
previously untreated patients in a mid-stage study, Gregory Everson of the
University of Colorado ...
- Keith Alcorn | 04 November 2013
A two-drug combination of direct-acting
antivirals developed by Merck achieved very high cure rates, with and without
ribavirin, in patients with genotype 1 hepatitis C infection in a small study
presented on Sunday ...
- Keith Alcorn | 04 November 2013
Two large studies of the 'baby-boom'
generation in the United States suggest that at least 50,000 US military
veterans have undiagnosed hepatitis C, and that around 80% of people with hepatitis C ...
- Keith Alcorn | 04 November 2013
A two-drug combination of direct-acting
antivirals developed by AbbVie achieved sustained virologic response in 95% of
previously untreated patients with genotype 1b hepatitis C infection after 12
weeks of treatment, without the need ...
- Liz Highleyman | 04 November 2013
Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the
duration of treatment and improves sustained response rates for HIV-positive
men with acute hepatitis C virus (HCV) infection, according to ...
- Liz Highleyman | 04 November 2013
Interferon-free
regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken
for 12 weeks produced sustained response in 100% of treatment-experienced
people with genotype 1 chronic hepatitis C virus (HCV) with advanced ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...